These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11442491)

  • 1. A cautionary tale: how to delete mouse haemopoietic stem cells with busulphan.
    Jopling C; Rosendaal M
    Br J Haematol; 2001 Jun; 113(4):970-4. PubMed ID: 11442491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo.
    Hassan Z; Hellström-Lindberg E; Alsadi S; Edgren M; Hägglund H; Hassan M
    Bone Marrow Transplant; 2002 Aug; 30(3):141-7. PubMed ID: 12189531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma.
    Ria R; Falzetti F; Ballanti S; Minelli O; Di Ianni M; Cimminiello M; Vacca A; Dammacco F; Martelli MF; Tabilio A
    Hematol J; 2004; 5(2):118-22. PubMed ID: 15048061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analysis of haemopoietic and microenvironmental populations of mouse bone marrow after treatment with busulphan.
    Molineux G; Testa NG; Massa G; Schofield R
    Biomed Pharmacother; 1986; 40(6):215-20. PubMed ID: 3539222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model.
    Ploemacher RE; Johnson KW; Rombouts EJ; Etienne K; Westerhof GR; Baumgart J; White-Scharf ME; Down JD
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):236-45. PubMed ID: 15077222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients.
    Westerhof GR; Ploemacher RE; Boudewijn A; Blokland I; Dillingh JH; McGown AT; Hadfield JA; Dawson MJ; Down JD
    Cancer Res; 2000 Oct; 60(19):5470-8. PubMed ID: 11034090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between ablation of distinct haematopoietic cell subsets and the development of donor bone marrow engraftment following recipient pretreatment with different alkylating drugs.
    Down JD; Boudewijn A; Dillingh JH; Fox BW; Ploemacher RE
    Br J Cancer; 1994 Oct; 70(4):611-6. PubMed ID: 7917905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
    Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
    Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose busulphan conditioning and neonatal stem cell transplantation preserves vision and restores hematopoiesis in severe murine osteopetrosis.
    Askmyr M; Holmberg J; Flores C; Ehinger M; Hjalt T; Richter J
    Exp Hematol; 2009 Feb; 37(2):302-8. PubMed ID: 19100677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.
    Schuler US; Renner UD; Kroschinsky F; Johne C; Jenke A; Naumann R; Bornhäuser M; Deeg HJ; Ehninger G
    Br J Haematol; 2001 Sep; 114(4):944-50. PubMed ID: 11564090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.
    Mattsson J; Uzunel M; Remberger M; Hassan M
    Bone Marrow Transplant; 2003 Sep; 32(5):477-83. PubMed ID: 12942093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum FLT-3 ligand in a busulphan-induced model of chronic bone marrow hypoplasia in the female CD-1 mouse.
    Molyneux G; Gibson FM; Whayman M; Turton JA
    Int J Exp Pathol; 2008 Apr; 89(2):159-70. PubMed ID: 18336532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of high dose busulphan on leukaemic progenitor cells in chronic myeloid leukaemia.
    Morstyn G; Sullivan J; Fairhead S; Cowling D; Hurley T
    Aust N Z J Med; 1981 Dec; 11(6):609-14. PubMed ID: 6949537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience.
    Olavarria E; Kanfer E; Szydlo R; O'Brien S; Craddock C; Apperley J; Goldman J
    Br J Haematol; 2000 Mar; 108(4):769-77. PubMed ID: 10792282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation.
    El-Serafi I; Remberger M; El-Serafi A; Benkessou F; Zheng W; Martell E; Ljungman P; Mattsson J; Hassan M
    Sci Rep; 2018 May; 8(1):8293. PubMed ID: 29844459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparative effect of busulphan ('Myleran') and aminochlorambucil on haemopoietic colony forming units in the rat.
    Dunn CD; Elson LA
    Cell Tissue Kinet; 1970 Apr; 3(2):131-41. PubMed ID: 4942743
    [No Abstract]   [Full Text] [Related]  

  • 17. Monitoring of Busulphan Concentrations in Children Undergone Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years.
    Faraci M; Tinelli C; Lanino E; Giardino S; Leoni M; Ferretti M; Castagnola E; Broglia M; De Silvestri A; Di Martino D; Bartoli A
    Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):173-181. PubMed ID: 28801891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo imaging studies of the effect of recipient conditioning, donor cell phenotype and antigen disparity on homing of haematopoietic cells to the bone marrow.
    Askenasy N; Farkas DL
    Br J Haematol; 2003 Feb; 120(3):505-15. PubMed ID: 12580970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marrow repopulation in mice treated with busulphan or isopropyl methane sulphonate and bone marrow.
    Massa G; Wyllie JP; Pratt AM; Molineux G; Schofield R
    Br J Haematol; 1987 May; 66(1):11-4. PubMed ID: 3036195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.